{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:29:33Z","timestamp":1697405373260},"reference-count":39,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.ejphar.2007.06.009","type":"journal-article","created":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T12:26:58Z","timestamp":1181824018000},"page":"207-212","source":"Crossref","is-referenced-by-count":4,"title":["Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model"],"prefix":"10.1016","volume":"572","author":[{"given":"Krishna S.","family":"Naruganahalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxminarayan G.","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwinkumar V.","family":"Meru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung B","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2007.06.009_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"issue":"Suppl., 11","key":"10.1016\/j.ejphar.2007.06.009_bib3","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ejphar.2007.06.009_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1472-8206.1999.tb00362.x","article-title":"Pharmacological characterization of muscarinic receptors implicated in rabbit detrusor muscle contraction and activation of inositol phospholipid hydrolysis in rabbit detrusor and parotid gland","volume":"13","author":"Barras","year":"1999","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ncpuro0672","article-title":"Mechanisms of disease: involvement of urothelium in bladder dysfunction","volume":"4","author":"Birder","year":"2007","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.eururo.2005.04.018","article-title":"Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur. Urol."},{"issue":"Suppl., 5A","key":"10.1016\/j.ejphar.2007.06.009_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0090-4295(02)01803-4","article-title":"Muscarinic receptor subtypes and management of the overactive bladder","volume":"60","author":"Chapple","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2007.06.009_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1474-8673.2002.00258.x","article-title":"Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional","volume":"22","author":"Chess-Williams","year":"2002","journal-title":"Auton. Autacoid Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0701920","article-title":"Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder muscle","volume":"124","author":"Choppin","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/01.ju.0000092557.02298.da","article-title":"Inhibition of hyperreflexia by vaginally administered oxybutynin: a novel rabbit model","volume":"171","author":"Chou","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1464-410x.2000.00444.x","article-title":"Comparative physiology and biochemistry of rat and rabbit urinary bladder","volume":"85","author":"Damaser","year":"2000","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2007.06.009_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejphar.2007.06.009_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","article-title":"M(3) muscarinic receptors mediate contraction of human urinary bladder","volume":"136","author":"Fetscher","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-2999(98)00214-3","article-title":"Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists","volume":"349","author":"Gillberg","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1569-9056(02)80508-5","article-title":"In vivo bladder selectivity of darifenacin, a new M3 antimuscarinic agent, in the anaesthetised dog","volume":"1","author":"Gupta","year":"2002","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.ejphar.2007.06.009_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2007.02.057","article-title":"Effect of the M3 selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve","author":"Iijima","year":"2007","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clinthera.2005.01.006","article-title":"Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly","volume":"27","author":"Kay","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2007.06.009_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00042307-200307000-00004","article-title":"Recent developments in the management of detrusor overactivity","volume":"13","author":"Kumar","year":"2003","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(17)51172-6","article-title":"Comparative pharmacological response of an in vitro whole bladder preparation (rabbit) with response of isolated smooth muscle strips","volume":"130","author":"Levin","year":"1983","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0022-5347(17)40115-7","article-title":"Comparative physiology and pharmacology of the cat and rabbit urinary bladder","volume":"143","author":"Levin","year":"1990","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/nau.1930130205","article-title":"Rabbit as a model of urinary bladder function","volume":"13","author":"Levin","year":"1994","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2007.06.009_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-2999(90)90032-2","article-title":"Characterisation of muscarinic acetylcholine receptors in human labial salivary glands","volume":"176","author":"Mei","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib26","series-title":"Poster Presented at the 2nd International Consultation on Incontinence Meeting. Paris, 2001","article-title":"Darifenacin is selective for the human recombinant M3 receptor subtype","author":"Napier","year":"2001"},{"key":"10.1016\/j.ejphar.2007.06.009_bib27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/jpet.104.067140","article-title":"Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland","volume":"310","author":"Nelson","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2007.06.009_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodine \u2014 a new bladder-selective antimuscarinics agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejphar.2004.03.044","article-title":"In vitro and in vivo tissue selective profile of solifenacin succinate (YM 905) for urinary bladder over salivary gland in rats","volume":"492","author":"Ohtake","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2007.06.009_bib31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1152\/japplphysiol.01546.2005","article-title":"Muscarinic receptors and salivary secretion","volume":"100","author":"Proctor","year":"2006","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib32","article-title":"Human idiopathic and neurogenic overactive bladders and the role of M(2) muscarinic receptors in contraction","author":"Stevens","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/13543784.15.9.1017","article-title":"Current and emerging investigational medical therapies for the treatment of overactive bladder","volume":"15","author":"Tiwari","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2007.06.009_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1474-8673.1995.tb00410.x","article-title":"Muscarinic receptor subtypes in the submandibular gland and the urinary bladder of the rabbit: in vivo and in vitro functional comparisons of receptor antagonists","volume":"15","author":"Tobin","year":"1995","journal-title":"J. Auton. Pharmacol."},{"key":"10.1016\/j.ejphar.2007.06.009_bib35","first-page":"959","article-title":"Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins","volume":"273","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.ejphar.2007.06.009_bib36","first-page":"56","article-title":"The overactive bladder: an overview for primary care health providers","volume":"44","author":"Wein","year":"1999","journal-title":"Int. J. Fertil. Womens Med."},{"key":"10.1016\/j.ejphar.2007.06.009_bib37","article-title":"The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat","volume":"120","author":"Williamson","year":"1997","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.ejphar.2007.06.009_bib38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00345-005-0507-3","article-title":"Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder","volume":"23","author":"Zinner","year":"2005","journal-title":"World J. Urol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907006802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299907006802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T03:04:13Z","timestamp":1587611053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299907006802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":39,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0014299907006802"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2007.06.009","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}